Lung Therapeutics, Inc. Strengthens Board of Directors with Appointment of Biopharmaceutical Veteran William C. Fairey
A recognized leader in specialty orphan drug development and commercialization, William C. Fairey joins Lung Therapeutics as new Board member
AUSTIN, Texas--(BUSINESS WIRE)-- Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary diseases and conditions, today announced the appointment of William C. Fairey to the Board of Directors. Fairey has 30 years of experience building strong and scalable global commercial organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005364/en/
William C. Fairey, Board Member, Lung Therapeutics, Inc. (Photo: Business Wire)
Brian Windsor, Ph.D., Lung Therapeutics Chief Executive Officer, said, “We are pleased that Bill Fairey has joined Lung Therapeutics’ Board of Directors. He brings a wealth of biopharmaceutical leadership and broad commercial expertise that will advance Lung Therapeutics’ strategy as we move through later stage development and into commercialization.”
“I am looking forward to working with the outstanding team at Lung Therapeutics. The company is developing promising and novel therapeutics that may help improve the lives of patients with serious forms of rare lung diseases,” said Bill Fairey.
Fairey’s extensive background includes serving as Executive Vice President and Chief Commercial Officer at MyoKardia, where he built the company’s commercial and portfolio strategy and established the European headquarters. As ChemoCentryx Chief Operating Officer he was responsible for building out the initial commercial and medical teams. Prior to ChemoCentryx, Fairey served in several roles at Actelion Pharmaceuticals, including developing Actelion’s Asia-Pacific business; chairing the Actelion China Board of Directors; serving as President of Actelion Canada; and becoming President of the U.S. division. He has served on the boards of the California Life Sciences Association and Rx&D, an association of Canada’s research-based pharmaceutical companies.
Fairey holds an MBA degree from Saint Mary’s College of California and a Bachelor of Science degree in Biology from the University of Oregon.
About Lung Therapeutics, Inc.
Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of novel therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead drug LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US. LTI-01 is currently in a Phase 2, randomized, placebo-controlled, double-blind, dose-ranging study evaluating LTI-01 in patients with infected, non-draining loculated pleural effusions. The company’s second product candidate, LTI-03, is in development for idiopathic pulmonary fibrosis. For more information, visit Lung Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005364/en/
Media Contact:
Sandra Oak
Nsight Public Relations
321-591-1508
soak@nsightpr.com
Company Contact:
Charles T. Garner
Chief Financial Officer
Lung Therapeutics, Inc.
737-802-1979
cgarner@lungtx.com
Source: Lung Therapeutics, Inc.